Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Results from phase I ALEXANDER study investigating the first CAR T-cell therapy, AUTO3, plus pembrolizumab to target both CD19 and CD22 in the treatment of R/R DLBCL

lymphomahub.com - Available CD19 chimeric antigen receptor (CAR) T-cells show activity in relapsed lymphoma, but long-lasting complete response rates remain below 40%. PD-L1 upregulation, that results in T-cell exhaustion, and CD19 antigen loss are thought to play a role in relapse.

Read the full article here

Related Content